CAMELOT FANTASIES
CAMELOT FANTASIES => Stocks Universe => Topic started by: Clay Death on November 11, 2014, 07:03:39 pm
-
https://seekingalpha.com/article/4135705-259-marijuana-stocks-horizons-marijuana-life-sciences-index-etf-jeff-sessions
-
https://www.newcannabisventures.com/be-prepared-for-consolidation-in-the-canadian-cannabis-sector-in-2018/
-
https://technical420.com/cannabis-article/california-rec-coming-and-these-companies-are-going-capitalize-big-way
-
https://seekingalpha.com/article/4134612-bak-portfolio-streets-paved-green
-
https://seekingalpha.com/article/4133494-244-marijuana-stocks-buying-winners-tracking-losers-2018?li_source=LI&li_medium=liftigniter-widget
-
https://finance.yahoo.com/news/canada-cannabis-market-could-explode-003000948.html
-
http://marijuanastocks.com/marijuana-stocks-top-trending-articles-on-black-friday-11242017/
-
Advanced Research & Development in Unique Cannabis Therapies to Battle Opioid Addiction for Safe Alternative Pain Relief
8:30 am ET November 28, 2017 (PR Newswire) Print
Studies are displaying evidence that new strains of cannabis can aid the battle against opioid addiction and in turn, create yet another new revenue opportunity in the burgeoning and vast cannabis landscape. As America fights an alarmingly disturbing opioid epidemic, the results of these studies could push legislators to continue paving the way for legal use of medical strains of cannabis throughout the country. Researchers studied patients using prescription opioids to treat chronic pain who enrolled in a recent program between 2010 and 2015 discovered patients using cannabis based therapies reported pain reduction, quality of life, social life, activity levels, and concentration, and few side effects from using cannabis one year after enrollment in the New Mexico study program. Active in the legal cannabis markets today include: Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF), Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF), Aphria Inc. (TSX: APH) (OTC: APHQF), Aurora Cannabis Inc. (TSX: ACB) (OTC: ACBFF), Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF)
Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) announces its research arm, Cannevert Therapeutics Ltd. ("CTL") filed a provisional patent application to US Patent and Trademark Office (the "USPTO") on September 13, 2017 for use of a specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement letter from the USPTO was received recently which provided a filing number of US 62/558,021 for this application. Read this and more news for Veritas Pharma at: http://www.marketnewsupdates.com/news/vrt.html
Opioids are substances that are derived from the opium poppy plant. They bind to the human body's own opioid receptors to provide pain relief or 'analgesia' for patients with acute or chronic pain when prescribed legally; morphine is an example opioid analgesic. Use of these drugs for a brief time is considered safe for pain management. However, when they are overprescribed and/or frequently misused, they produce a sense of euphoria along with relieving pain. Hence, drug dependence can occur despite using them as prescribed over prolonged periods with the potential of fatal overdose. Opioid overdose contributed to more than 33,000 deaths in 2015 according to US Centers for Disease Control and Prevention. Heroin and fentanyl are the most widely known opioids for their illegal, recreational use, abuse potential and fatal overdoses. Cannabis contains substances called cannabinoids that appear to bind to human body's own cannabinoid receptors to also produce similar effects to those of the body's opioids in mediating analgesia and behavioral effects. However, they do not have the same drug dependence or overdose potential. When cannabinoids and opioids are combined, they appear to augment each other's effects synergistically. Therefore, the combination may allow for opioids to be used at lower doses with fewer side effects for the treatment of pain and related addiction. According Coherent Market Insights*, the global opioids market was approximately USD $17b in 2015 and is forecasted to moderately increase to near USD $26 bn in 2024. It indicates that legal cannabis is expected to impact the opioids market growth as it gets adopted as a safe alternative pain relieving therapy to opioids and it is increasingly being used to address related addiction. According to the World Drug Report 2016, approximately 17 million people suffered from opioid drug abuse.
Veritas CEO, Dr. Lui Franciosi stated, "We are pleased with Cannevert's latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for patients." Dr. Franciosi goes on to say, "This strain could be also potentially useful in addressing the current fentanyl crisis throughout North America. If we're targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that clinicians can rely upon."Also, to note, the Company will be issuing 1.1 million stock options based on today's closing price of CAN$0.81 cents.
In other industry developments and market performances of note:
Canopy Growth Corporation (TSX: WEED.TO) (OTC: TWMJF) is continuing to develop its hemp operations. It has entered into a definitive agreement to acquire certain assets and intellectual property from Green Hemp Industries Ltd. and its principal, Jason Green. Mr. Green is a veteran hemp farm operator based in Saskatchewan. The transaction marks a major milestone in Canopy Growth's hemp business and is expected to enhance Canopy Growth's vertically integrated field-scale hemp production capabilities. In addition to acquiring Green's farm operations and associated assets, equipment, genetic stock, and other property, Canopy Growth will operate approximately 300 acres of existing hemp production after completion of the transaction, which it anticipates will be scalable to 2,200 acres for the 2018 growing season.
Aphria Inc. (TSX: APH.TO) (OTCQB: APHQF) has achieved another milestone as part of its expansion strategy, obtaining its dealer's license pursuant to the Controlled Drugs and Substances Act under Health Canada. This permits the company to possess, sell and transport medical cannabis oil and resin to international markets. "There is an incredible appetite for high-quality medical cannabis in legal markets around the world. Obtaining our dealer's license is a significant milestone in our international expansion strategy as it enables Aphria to have greater control over importing and exporting medical cannabis oil globally," said Vic Neufeld, Chief Executive Officer of Aphria. "This license will accelerate our speed to international markets and broaden our patient base internationally, resulting in greater revenue for Aphria."
Aurora Cannabis Inc. (TSX: ACB.TO) (OTCQX: ACBFF) wholly owned subsidiary BC Northern Lights (BCNL) and Namaste Technologies Inc. have signed a hardware supply agreement whereby Namaste will be the first third party distributor to sell BCNL's premium home cultivation systems and accessories through its on-line technology platform. Namaste will roll out same-day delivery service of select BCNL products to the Greater Toronto Area (GTA), as well as next-day delivery in most other parts of Canada, to help meet the growth in demand for home gardening systems anticipated with the passing of the federal Cannabis Act to legalize adult consumer use, as well as continued rapid growth of the medical cannabis market.
Isodiol International Inc. (CSE: ISOL.CN) (OTCQB: ISOLF) recently announced it has entered into a binding agreement to acquire 100% of C3 Global Biosciences (C3GBS), a cause driven organization committed to developing sustainable health solutions through the advancement of cannabis science. "Isodiol and C3GBS are truly complementary. We look forward to bringing the C3GBS brand and world class team onboard to pursue the shared vision of providing consumers with the highest quality of bioactive CBD products," said Marcos Agramont, CEO of Isodiol. "By combining the two companies, we can align our efforts strategically to further strengthen our portfolio of assets. This partnership will be aimed at increasing market expertise as we establish both companies as leaders in the CBD market."
-
https://hightimes.com/medicinal/study-finds-medical-marijuana-is-helping-kids-with-cerebral-palsy/
-
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=7939385678280709&topic=MARKCOMM&symbology=null&cp=null&webmasterId=90338
Canada’s Cannabis Industry: Weed Picking Up Speed
As Canada prepares for the lifting of cannabis prohibition with legalization in July of 2018, there’s a push to increase the number of licensed producers.
Leading companies in this space include Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF), Aurora Cannabis (TSXV: ACB) (OTC: ACBFF), MedReleaf Corp. (OTC: MEDFF), and MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF).
Already, Health Canada has stepped up its game in granting Access to Cannabis for Medical Purposes Regulations (ACMPR) licences and expects to up the amount even more through the end of the year by streamlining the process.
This provides a window on the state of the industry and shows why markets are also embracing the coming rise.
The increased pace of growth has broadened the entry point that once was limited to major producers such as Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF). That stock rose as high as $13 per share in February of 2017, but has since settled back to the $10 level.
In the process, a number of nimble new competitors have entered the game and made serious inroads toward mass production.
Early cannabis contributors following their success model include Aurora Cannabis (TSXV: ACB) (OTC: ACBFF), and MedReleaf Corp. (OTC: MEDFF), who are both leading the Licenced Producer category, as well as relative newcomer MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF). MYM is gaining attention as it rolls out plans for one of the world’s largest cannabis greenhouses that will dwarf all other operators.
MOMENTUM CARRIES
The potential $22.6 billion cannabis industry is still in its early stages, and for investors there seems to be no limit on the potential value this sector can offer. And the momentum is driving everything.
Beyond basic medicinal or recreational consumption, cannabis offers several other high value derivatives that provide major potential for the industry as a whole.
The most widely used is the Cannabidiol compound of the plant, referred to as CBD.
CBD-only products deliver much of the medicinal benefits of the cannabis plant, only without the high that’s typically attributed to cannabis’ other yield, THC. That’s why you’ll notice CBD used in all types of therapeutic products from topical ointments to beverages and a wide variety of food products.
Legal in all 50 US states and Canada, CBD was responsible for $170 million in the US 2016, and is projected to hit $1 billion by 2020. The American marijuana industry as a whole is expected to hit $50 billion by 2026.
In order to reach a $50 billion market from its current state is going to require industry wide expansion with a focus first and foremost on growing capabilities. These need to expand, and at a pretty rapid pace.
MASS CULTIVATION IS KEY
To accommodate expansion, the cannabis industry is wrapped in a race to build the biggest, best, most sophisticated greenhouses in the world – and they’re succeeding.
Canopy’s Tweed facility in Niagara-on-the-Lake, Ontario, which covers 350,000 square feet of greenhouse space is currently the clear leader and the world’s largest marijuana greenhouse.
But that won’t last long.
Competitors such as at Aurora Cannabis began work on their Leduc facility near the Edmonton Airport, which is to be more than double the size, at a whopping 800,000 square feet of growing space.
That facility has a projected growing capacity of 100,000 kgs of cannabis annually.
No to be outdone, AmeriCann Inc. (OTC: ACAN) is planning to surpass Aurora’s new space, and has announced plans to build the largest cannabis greenhouse facility in the USA at roughly 1 million square feet to be located in Massachusetts.
But, here’s where MYM leapfrogs all of their plans: MYM Nutraceuticals and its majority-owned subsidiary CannCanada signed an exclusive deal with the Quebec municipality of Weedon to build a 1.5 million-square-foot cannabis production facility consisting of fifteen 100,000-square-foot-greenhouses.
As envisioned, this massive marijuana operation will be one of the largest grow operations on the planet, with the potential to produce over 150,000 kgs of cannabis per year—or roughly $750,000,000 annually at current market value.
That’s three quarters of a billion dollars in annual production from a single cannabis operation.
MYM’S SMART PLAY
MYM Nutraceuticals has taken a brilliant tact in locating its new facilities.
The cannabis producer has worked in tandem with the municipality in Weedon to create jobs and spark an entire industry in the process. Accordingly, the plans will see Weedon itself acquiring the 329 acres of land for MYM to build on.
The first phase of the Weedon plan, which accounts for 300,000 square feet of greenhouse space, has both architectural and security plans completed. The additional four phases are still in development.
While the Weedon facility is at the forefront, MYM has advanced on another Quebec-based project, with the recent approval and permitting to begin construction on the company’s smaller facility in Laval.
The Laval facility is expected to have the capacity of producing 1,000 kgs. of cannabis annually and is scheduled for completion by the end of Q4 2017.
MYM is also diversified across much of the cannabis sector, from growth, to formulation and production, to branding and distribution.
Its operations are cover wide ranging assets, from CannaCanada in Weedon, to its Licensed Producer subsidiary Sublime in Montreal, along with products and branded entities Joshua Tree, MyHemp Skin Therapy, and HempMed.
At this point it has the assets advance rapidly up the ranks of the Cannabis heavy weights. Unlike those companies with market caps from $800 million to $1.5 billion, MYM Nutraceuticals remains undervalued at just a $27 million market cap.
Although one of the newcomers, MYM has already made an impression by more than doubling its value since it began trading in March of 2017.
POTENTIAL COMPARABLES
Aurora Cannabis (TSXV: ACB) (OTC: ACBFF)
Through its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., Aurora Cannabis is a major LP, operating a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta. Aurora made waves when it announced the construction of its 800,000 square foot “Aurora Sky” facility second 800,000 square foot production facility at the Edmonton International Airport. Aurora’s also involved in Quebec, with its third 40,000 square foot production facility set to be completed in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also holds a minority stake in leading extraction technology company Radient Technologies Inc., based in Edmonton, and a minority stake in Australian company Cann Group Limited, which was the first in Australia to conduct research on and cultivate medical cannabis. Aurora also owns German wholesale importer, exporter, and EU medical cannabis distributor Pedanios.
MedReleaf Corp. (OTC: MEDFF)
MedReleaf sets The Medical Grade Standard for cannabis in Canada and around the world. The first and only ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF)
The granddaddy of the corporate cannabis sector, Canopy Growth is the world’s largest diversified cannabis company. Canopy boasts a wide offering of distinct brands and curated cannabis varieties in dried, oil and capsule forms. Most widely recognized is Canopy’s subsidiary Tweed which is the world’s most recognized marijuana production brand, as well as an industry educator. Accompanying Tweed in Canopy’s portfolio is medical-grade cannabis producers Bedrocan Canada. In total, Canopy Growth’s numerous state-of-the-art production facilities total over half a million square feet of GMP-certified indoor and greenhouse production capacity.
For a more in-depth look into MYM you can view the in-depth report at USA News Group: http://usanewsgroup.com/2017/11/12/the_marijuana_boom_is_here_to_stay-2-2-2-2/
USA News Group
http://usanewsgroup.com
info@usanewsgroup.com
Legal Disclaimer/Disclosure:
Disclaimer: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Source: Livemoney US Market Commentary (November 17, 2017 - 7:27 AM EST)
News by QuoteMedia
www.quotemedia.com
-
Rising Demand for Cannabis Oils Pushes Canada's Producers Into Overdrive
8:30 am ET November 15, 2017 (PR Newswire) Print
Licensed cannabis producers in Canada are growing at remarkable pace, swept forward by the country's legalization of medicinal marijuana in 2001 and impending legalization for recreational use of the plant, set for July 1, 2018. Amid demand for cannabis in various forms, oils are a significant contributor to the growth of leading producers that are keeping an eye on evolving market trends (http://nnw.fm/Xa32z). Key industry players such as ABcann Global Corp. (OTC ABCCF) (TSX-V: ABCN) (ABCCF Profile), Emblem Cannabis, Inc. (OTC: EMMBF) (TSX-V: EMC), Emerald Health Therapeutics, Inc. (OTC: EMHTF) (TSX-V: EMH), OrganiGram Holdings, Inc. (OTC: OGRMF) (TSX-V: OGI) and Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSX-V: FIRE) are leading the industry and adjusting their strategies to include mounting consumer demand for oils.
ABcann Global (OTCQB: ABCCF) (TSX.V: ABCN) is leveraging its position as a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis to expand its product line to include cannabis oils. As one of Canada's first licensed cannabis producers, ABcann is significantly ahead of the curve when it comes to production capacities. The company's licensed and fully operational Vanluven Facility produces 1,000 kg annually. Construction on the company's Kimmett facility, an industry-leading, purpose-built, world class style facility, is under contract with another 65 acres under full Abcann ownership for future expansion plans. As noted in its corporate presentation (http://nnw.fm/W6rbx), ABcann's yield per square foot is 100 percent over the industry average.
Pivoting off its deep roots in pharmaceutical-grade cannabis, ABcann's wholly owned ABcann Medicinals, Inc. subsidiary in August launched CBD-Med, one of Canada's highest legal CBD:THC (cannabidol:tetrahydrocannabinol) ratio products available on the market (http://nnw.fm/sYv7g), under Health Canada regulations.
The launch of CBD-Med is on par with ABcann's broader strategy to diversify its product line and capture its share of demand for cannabis oils. Products that ABcann will have available for patients are expected to include a 1-1 THC/CBD drop, a high THC dropper and a high CBD dropper.
"The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis," ABcann's executive chairman stated in the press release. "As the Company continues to scale production capacity, our product line will expand as we strive to increase shareholder value through capturing a larger market share of the current global medical markets."
CBD-Med's high CBD content is a vital differentiating factor. Although the virtues of THC have been loudly sung, many patients exhibit adverse reactions, such as short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks to the cannabinoid. On the other hand, CBD is devoid of such side effects and, moreover, appears to mitigate the injurious effects of THC when taken in conjunction with it.
More than half (54%) the cannabis strains on the Canadian market have a high THC-CBD ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD below 1%. Only 14% of strains have both THC and CBD levels that exceed 5%. And just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which CBD-Med can be found.
Emblem Cannabis, Inc. (OTC: EMMBF) (TSX-V: EMC.V) is also strategizing for its share of the market. Earlier this month the company was granted a license to sell cannabis oils (http://nnw.fm/0rdcB ). Late last year, Emblem was granted a supplemental license for the production of cannabis extracts. John Stewart, President of Emblem's Pharmaceutical Division has emphasized the importance of this license to the company's plan to provide high quality, differentiated cannabis products, in a variety of formats. Emblem plans to offer a selection of cannabis oils, including those from CBD dominant strains, THC dominant strains and strains with both CBD and THC content. The company believes cannabis oils and related formulations provide a level of consistency and dosage accuracy that cannot be achieved with dried flower. Such products also provide a method of consumption that many consumers find to be substantially more precise and convenient.
Meanwhile, Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) (TSX-V: EMH.V), through its Emerald Health Botanicals subsidiary, as a licensed producer is already offering eight oils with varying levels of THC, THCA, CBD, and THC to CBD ratios. The product line includes the company's recently launched CBD-25 and CBD-50 medical cannabis oils containing approximately 25 milligrams and 50 mg of CBD per milliliter (http://nnw.fm/mSfc3). The company believes that CBD-50 will provide a unique treatment option to doctors and patients seeking high CBD potency with minimal THC. Its management is of the opinion that CBD-50 contains the highest amount of CBD per milliliter on the ACMPR market today. Emerald Health Botanicals is now licensed to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. The subsidiary currently operates an indoor facility in Victoria, BC, and is making progress on expansion plans for a 32-acre property in Metro Vancouver and a joint venture with Village Farms that utilizes a 25-acre existing greenhouse complex in Delta, BC.
Moncton, New Brunswick-based OrganiGram Holdings, Inc. (OTC: OGRMF) (TSX-V: OGI.V) in June received an upgrade to its licensed producer status (http://nnw.fm/47QlM), allowing both the production and sale of cannabis oil extracts, as well as the company's current dried medical cannabis products. Quickly acting on that approval, OrganiGram released Shubie, a pure CBD edible oil that expands its range of cannabis oil offerings. Shubie is an ethanol-extracted cannabis oil formulated in an organic sunflower oil base (http://nnw.fm/RTd4Y). This 50ml formulation boasts 23.7 mg/ml CBD and 1.39 mg/ml THC. Like the other oils in the OrganiGram line up, Shubie was named for an iconic Atlantic Canadian waterway, the Shubenacadie River.
Supreme Pharmaceuticals' (OTC: SPRWF) (TSX-V: FIRE.V) wholly owned 7ACRES subsidiary recently received approval from Health Canada to begin cultivation at its 30,000 square-foot flowering rooms at the company's hybrid grow facility. The additional flowering rooms increases the size of 7ACRES' flowering facility to 40,000 square feet. 7ACRES, and thus Supreme, also has its footing in oils via a retail partnership with Aurora Cannabis (TSX: ACB) (OTC: ACBFF). In its fourth-quarter financial results, Aurora said sales of dried medical cannabis and cannabis oils contributed $5.6 million to revenues, of which $0.4 million (7.1%) was generated in Germany and $5.2 million in Canada (http://nnw.fm/MOgY2 ).
Adoption of cannabis oil continues to increase as a preferred alternative to cannabinoid consumption, providing cannabis cultivators with an unprecedented market opportunity paced by rising consumer demand.
For more information on ABcann Global please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)
About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).
About IBBN Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Based Brand Network (IBBN) http://www.InvestorBasedBrandNetwork.com
Corporate Communications Contact: NetworkNewsWire (NNW) +1-212-418-1217 Editor@NetworkNewsWire.com Media Contact: FN Media Group, LLC NNW@FinancialNewsMedia.com +1-(954)345-0611
http://www.NetworkNewsWire.com
SOURCE NetworkNewsWire
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201711151846&Transmission_Id=201711150830PR_NEWS_USPR_____enUK201711151846&DateId=20171115
-
Cannabis Infused Products Generating Mouth-watering Opportunities Across North American Legal Marijuana Industry
8:30 am ET November 15, 2017 (PR Newswire) Print
Innovation is a driving force behind enormous growth in the Legal Cannabis markets across the U.S. and Canada as new CBD Infused products continue to gain in popularity for consuming cannabis while exploring alternative choices to smoking. Even alcohol giant, Constellation Brands is keeping tabs on the marijuana industry as reports indicates the company is looking to pay about $191 million for a stake in a well known, large Canadian seller of medicinal-marijuana products. Although the company recently said it has no plans to sell cannabis in the U.S. or other markets until it's legal "at all government levels but for now, it's more a matter of identifying markets with growth potential", said Chief Executive Officer Rob Sands. Cannabis companies in the markets this week with developments include: Puration, Inc. (OTC: PURA), GreenGro Technologies Inc. (OTC: GRNH), CV Sciences Inc. (OTC: CVSI), Aurora Cannabis Inc. (OTC: ACBFF) (TSX: ACB), Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF).
Puration, Inc. (OTC: PURA) today announced the company plans to have a cannabis infused beverage ready to launch in Canada in conjunction with the nationwide legalization of recreational marijuana expected in Canada in July of 2018. Deloitte estimates the market for legal marijuana in Canada could reach $8 billion . The Canadian Spirits market is $5 billion. "I originally became a Puration shareholder when I purchased the Puration distribution rights for Canada," said Brian Shibley, CEO of Puration. "I am a Canadian citizen and with my experience and contacts in Canada, I became interested some time ago in distributing Puration products in Canada. One thing has led to another and Puration has evolved. My interest in Puration has since grown, and so I have become the CEO. With the pending nationwide legalization of recreational marijuana in Canada, combined with Puration's experience in cannabis extractions and making cannabis infused beverages, I am even more enthusiastic today about distributing Puration products in Canada then when I originally came to the company. I think Puration's success with EVERx CBD Infused Water is laudable, but I think the opportunity to introduce a THC infused beverage in Canada is a much bigger opportunity than EVERx." Read this and more news for Puration at http://www.marketnewsupdates.com/news/pura.html
Puration has licensed a patented process for extracting cannabinoids from the cannabis plant. Today the company produces and markets a CBD Infused Sports Water. Puration introduced EVERx CBD Infused Sports Water earlier this year in March at Arnold Schwarzenegger's Annual Arnold Sports Festival (formerly the Arnold Classic) in Columbus, Ohio. The Arnold is host to more athletes than the Olympics with over 70 sporting events and over 18,000 athletes. EVERx CBD Infused Sports Water was featured in September at Joe Weider's Olympia Fitness and Performance Expo In Las Vegas. EVERx CBD Infused Sports Water is also now on shelves at Drug Emporium. The company recently announced adding Strawberry Kiwi and Lemon Lime flavors to its EVERx CBD Infused Sports Water. EVERx has become a leading brand name in the CBD infused marketplace and one of the only CBD infused products in the sports nutrition marketplace.
In other industry developments and market activity:
GreenGro Technologies Inc. (OTC: GRNH) closed up over 2% with over 2.3 million shares traded by the market close on Tuesday. GreenGro Technologies announced late last month that it has executed a lease on 4-acres of property in a commercial agriculture zoned region of Southern California, completed set-up of the Company's greenhouse and readies for production. "Greenhouse-number-one will be operated by the horticulture experts at The Greenhouse Collect, a non-profit organization serving medical marijuana patients since 2014.
CV Sciences Inc. (OTCQB: CVSI) closed Tuesday up 6% at $0.2385 with nearly one million shares traded on the day. The company recently announced it has been named on Deloitte's Technology Fast 500(TM), an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences growing by 403% during this period. CV Sciences' President and CEO, Michael J. Mona, comments, "We are proud to be named among the fastest growing technology companies in North America by Deloitte. This prestigious award reflects CV Sciences' market leadership and our dedication to developing products that improve health and patient outcomes. We are honored by this recognition and look forward to the Company's continued growth."
Aurora Cannabis Inc. (OTCQX: ACBFF) (TSX: ACB.TO) closed up over 7% on Tuesday at $5.04 trading over 9.6 million shares on the OTC Markets and also closed up over 7% on the Toronto Exchange at $6.41 on heavy trading volume of 63.4 Million shares traded by the market close. The company also announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held in Edmonton, Alberta, on November 13, 2017. The total number of shares represented by shareholders present in person and by proxy at the meeting was 88,726,591 million representing 23.86 per cent of Aurora's issued and outstanding Common Shares. All of the matters put forward before shareholders for consideration and approval as set out in the Company's Management Information Circular dated October 6, 2017, were approved by the requisite majority of votes cast at the Meeting.
Cannabix Technologies Inc. (CSE: BLO.CN) (OTC: BLOZF) closed up over 64% on Tuesday at $1.61 trading over 8 Millions shares on the Canadian CSE Exchange and also closed up over 64% at $1.27 trading over 2.3 Million shares on the OTC Markets. The company recently announced that the Company has been listed as one of the "50 Innovations to Watch" in British Columbia by Business in Vancouver ("BIV") magazine. According to BIV, the special edition magazine, "lists 50 made in B.C. innovations that are making waves across the province, the country and the world." The list includes companies from a wide range of industries such as technology, financial services, clean tech and consumer products, and includes prominent B.C. companies like Lululemon Athletica, Ballard Power Systems, and Mogo Finance.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty one hundred dollars for news coverage of the current press release issued by Puration, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact email: info@marketnewsupdates.com +1(561)325-8757
SOURCE MarketNewsUpdates.com
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201711151845&Transmission_Id=201711150830PR_NEWS_USPR_____enUK201711151845&DateId=20171115
-
Who's ready Jeff Sessions?
Thank you for the information.
May I ask you for assistance next week
I will be ready to invest.
he is the attorney general of the united states.
he is a **** idiot. trump owed him a favor so he made him the attorney general.
he is against the cannabis movement and the cannabis initiatives.
-
CANNA-DIANS CELEBRATE CANADA AND CANNABIS DAY JULY 1ST
July 1st, 2017 was a huge day for Canada- not only was it Canada’s 150th birthday, it was the 22nd annual Cannabis Day- bringing Canna-dians across the country together to celebrate.
This Cannabis Day was historic for two reasons- one, it was held for the first time at Thornton Park, and two, it will be the last Cannabis Day where cannabis is illegal (assuming all goes to plan!).
Whatever reason brought you to Cannabis Day, whether it was its famous Farmer’s Market, the live bands, or the array of speakers including Jodie Emery, Dana Larsen, and Freddie Pritchard, it was a day of joy and joints for all.
Thornton Park gave attendees more room to breathe (and smoke!) than the Vancouver Art Gallery which was Cannabis Day’s previous home for over two decades. Craig Ex, from Expert Joints, was broadcasting live for Pot TV and said that “Thornton Park was leaps and bounds better than the Art Gallery”, describing the overall vibe as “extremely positive”. That was great news, considering the drama of the past two years which has included arrests and an attempted takeover by a rival group.
Dana Larsen, one of the featured speakers and co-organizers, said that “Cannabis Day is a nice alternative to many booze-fests also happening on Canada Day”, and when you looked around the large crowd of relaxed and peaceful chronnoiseurs, you couldn’t help but agree.
Source: https://cannabislifenetwork.com/canna-dians-celebrate-canada-and-cannabis-day-july-1st/
wow.
fascinating.
-
CANNA-DIANS CELEBRATE CANADA AND CANNABIS DAY JULY 1ST
July 1st, 2017 was a huge day for Canada- not only was it Canada’s 150th birthday, it was the 22nd annual Cannabis Day- bringing Canna-dians across the country together to celebrate.
This Cannabis Day was historic for two reasons- one, it was held for the first time at Thornton Park, and two, it will be the last Cannabis Day where cannabis is illegal (assuming all goes to plan!).
Whatever reason brought you to Cannabis Day, whether it was its famous Farmer’s Market, the live bands, or the array of speakers including Jodie Emery, Dana Larsen, and Freddie Pritchard, it was a day of joy and joints for all.
Thornton Park gave attendees more room to breathe (and smoke!) than the Vancouver Art Gallery which was Cannabis Day’s previous home for over two decades. Craig Ex, from Expert Joints, was broadcasting live for Pot TV and said that “Thornton Park was leaps and bounds better than the Art Gallery”, describing the overall vibe as “extremely positive”. That was great news, considering the drama of the past two years which has included arrests and an attempted takeover by a rival group.
Dana Larsen, one of the featured speakers and co-organizers, said that “Cannabis Day is a nice alternative to many booze-fests also happening on Canada Day”, and when you looked around the large crowd of relaxed and peaceful chronnoiseurs, you couldn’t help but agree.
Source: https://cannabislifenetwork.com/canna-dians-celebrate-canada-and-cannabis-day-july-1st/
-
Who's ready Jeff Sessions?
Thank you for the information.
May I ask you for assistance next week
I will be ready to invest.
-
Thank you for all the information General. Awesome
you are welcome lady Divine.
I think we have to start taking a good look at the Canadian cannabis stocks.
jeff sessions is killing all the momentum in the American cannabis stocks.
-
Thank you for all the information General. Awesome
-
http://www.thecannabist.co/2017/04/30/raphael-mechoula-cannabis-research-cbd/78654/
-
http://www.otcmarkets.com/stock/MJNA/news/Study-Results---Medical-Marijuana--Inc--Subsidiary-HempMeds-reg--Mexico-Announces-Release-Of-Study-Using-Its-Real-Scientific-Hemp-Oil-X-trade--To-Treat-Epileptic-Children?id=153300&b=y
-
Cannabis Product Development for Cannabinoid CBD - THC Oil Formulas Leading to Higher Quality Medicinal Marijuana Therapies
8:45 am ET February 22, 2017 (PR Newswire) Print
The intersection of Biotech & Cannabis Industries is becoming more and more prevalent today resulting in identifying and researching the development Of Cannabinoids & THC Extracts as well as other botanicals for discovering the newest and innovative approach to medicinal cannabis and marijuana therapies and their applications. Cannabis companies are forging ahead by acquiring new relationships and assets designed to bring the new therapies to the market place around the globe. Market performers and latest breaking news for Cannabis companies include: Vinergy Resources Ltd. (OTC: VNNYF) (CSE: VIN.CN), Future Farm Technologies Inc. (OTC: AGSTF) (CSE: FFT.CN), Cannabics Pharmaceuticals Inc. (OTC: CNBX), OWC Pharmaceutical Research Corp. (OTC: OWCP) and Canopy Growth Corporation (OTC: TWMJF)(TSX: WEED.TO).
Vinergy Resources Ltd (OTCQB: VNNYF) (CSE:VIN), in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has signed a binding Letter of Intent ("LOI") to acquire 65% of Biolennia Laboratories Inc. (the "Laboratory").
Biolennia will provide a host of drug testing services to support MJ BioPharma's product line and provide research and development (R&D), product formulation, extraction facilities, systems design and develop standard-operating-procedures (SOPs). The lab is currently in the process of applying for a Dealer's License from Health Canada. Once issued, the license will allow the Company to process cultivated cannabis (extracts and/or derivatives) for R&D purposes. Read this and more news for Vinergy Resources at: http://marketnewsupdates.com/news/vnnyf.html
Biolennia was founded in 2001 by Dean Swift as the internal R&D and quality testing laboratory to support Micrylium Laboratories Inc. ("Micrylium"). In 2002 it upgraded to a full active ingredient and microbial testing laboratory for several Health Canada approved products. Biolennia is a specialty development laboratory with expertise in Microbiology (bacteria, fungi, viruses), Chemistry (proteins, enzymes, drug testing, material science and analytics). The Laboratory currently provides testing, R&D and quality control for a proprietary line of Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrlylium.
Biolennia has in-house expertise in methods accepted by Health Canada and the Federal Drug Administration (FDA) for determining purity and quality of many of the materials and methods used in validating cannabis and or testing cannabis products. Biolennia brings a highly talented team of Microbiologists who are familiar with testing high purity water, ethanol, ethyl acetate, propylene glycol, xylitol, glycerine, propandiaol, d-limonene, myrcene, and beta caryophelline.
Under the terms of the acquisition Vinergy/MJ BioPharma will acquire 65% of Biolennia for CAD $260,000 and 150,000 shares of Vinergy at the time the definitive agreement is signed. The Company expects to close on the acquisition in Q1-2017. "This is a fantastic acquisition for us and supports our entire product line and R&D initiatives moving forward. Our technical expertise in drug testing, extractions, and formulas containing CBD, Terpene, THC and other botanicals is continually being furthered. We have a remarkable team. We feel strongly that science based products formulated from extracts and derivatives that are properly dosed and manufactured in GMP environments to ensure consistency and safety for all customers whether they be recreational or medical users, is the future of the cannabis industry," MJ BioPharma CEO Kent A. Deuters.
Breakthrough performances in the markets this week and recent developments include:
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) closed up over 128% on Tuesday at $2.09 trading over 14.9 Million shares by the market close. OWC Pharmaceutical Research, through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
Future Farm Technologies Inc. (OTCQB: AGSTF) (CSE: FFT.CN) closed up over 40% on Tuesday at $0.485 trading over 5.7 Million shares by the market close. Future Farm Technologies reported this week that its subsidiary, FFM Consulting Services, LLC, a California limited liability company, has entered into a management agreement with a California non-profit company. The non-profit has secured a sublicense to legally manufacture cannabis oil using a non-volatile method compliant under the Medical Marijuana Regulation And Safety Act ("MMRSA"), in South-eastern Los Angeles County, California.
Future Farm also announced that due to a high level of interest from strategic investors they are offering $1,000,000 (units) in a non-brokered private placement. The Company will use the net proceeds for opportunistic acquisitions, and the continued rapid expansion of their business. The Company is offering each Unit at a price of $0.27 CDN per Unit. Each Unit is comprised of one common share of stock and one-half share purchase warrant that is exercisable at $0.37 CDN per common share for one-year with certain acceleration clauses.
Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO) closed up on the OTC market at $9.73 and $12.80 on the TSX trading over 1.6 Million shares on Tuesday on the TSX exchange alone. Canopy Growth Corporation announced that it has entered into a memorandum of understanding ("MOU") with Namaste Technologies Inc. ("Namaste"), an emerging leader in the vaporizer and accessories space with 26 e-commerce retail stores in 20 countries. This MOU represents an opportunity for the companies to work together to educate customers on the legal, regulated cannabis framework in Canada, encourage the use of vaporizing technology over smoking, and introduce cross-brand exposure among their respective clients. Namaste's database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) closed up over 60% on Tuesday at $6.45 trading over 6.7 Million shares by the market close. Cannabics Pharmaceuticals, a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
-
Pure Cannabis Concentrate & CBD Oil Product Demand Escalates in Legal Marijuana Market
8:30 am ET February 21, 2017 (PR Newswire) Print
As the United States and Canada continues to make strides towards legalization of cannabis, the demand for pure cannabis extracts for THC & CBD oils are steadily rising at a quick pace. Cannabis operators and purveyors are acquiring advanced licenses and other assets to gain an edge on competitors in the race to improve higher grades of cannabis concentrate and CBD extraction methods as the demand rises across North America and globally. Cannabis companies in the news today include Future Farm Technologies Inc. (OTC: AGSTF) (CSE: FFT.CN), Mentor Capital, Inc. (OTC: MNTR), Cannabics Pharmaceuticals Inc. (OTC: CNBX), OWC Pharmaceutical Research Corp. (OTC: OWCP) and Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO)
Future Farm Technologies Inc. (OTCQB: AGSTF) (CSE: FFT.CN) is pleased to announce that its subsidiary, FFM Consulting Services, LLC, a California limited liability company, has entered into a management agreement with a California non-profit company. The non-profit has secured a sublicense to legally manufacture cannabis oil using a non-volatile method compliant under the Medical Marijuana Regulation and Safety Act ("MMRSA"), in southeastern Los Angeles County, California.
The non-profit will produce highly pure cannabis concentrates to supply California's medical marijuana patients' rapidly growing demand for both THC and CBD oil. The company will also focus on increasing inventory and capacity as California prepares to create a market for legal recreational cannabis. FFM Consulting Services, LLC, which is majority owned by Future Farm Technologies, will manage the new state-of-the-art extraction facility. Read this and more news for Future Farm Technologies at http://marketnewsupdates.com/news/agstf.html
"We're thrilled to have reached this major milestone for our emerging company and excited to have the opportunity to manage this extraction facility as it allows us to showcase our ability to expertly manage the production of consistent and pure concentrates," said Bill Gildea CEO of Future Farm Technologies. Cannabis concentrates and edibles are the largest and fastest growing segments of the cannabis market. The market is accelerating as consumers become more educated on the various oil infused products that can be produced, as well as how well they work. As consumers become more educated, they grow more interested in using oil as a flower alternative.
Future Farm is also pleased to announce that due to a high level of interest from strategic investors, they are offering $1,000,000 (units) in a non-brokered private placement. The Company will use the net proceeds for opportunistic acquisitions, and the continued rapid expansion of their business. The Company is offering each Unit at a price of $0.27 CDN per Unit. Each Unit is comprised of one common share of stock and one-half share purchase warrant that is exercisable at $0.37 CDN per common share for one-year with certain acceleration clauses.
In other Cannabis market performances and developments of note in the sector:
Mentor Capital, Inc. (OTCQB: MNTR) closed up on last Friday at $2.84 trading over 1 million shares by the market close. Mentor Capital is a private equity firm specializing in acquisitions and emerging growth investments. The firm provides passive equity funding and liquidity to smaller companies and owners in the medical, marijuana and social use cannabis companies.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) closed up over 36% on last Friday at $4 trading over 8.2 Million shares by the market close. Cannabics Pharmaceuticals, a U.S-based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) closed up over 36% on last Friday at $0.92 trading over 6.7 Million shares by the market close. OWC Pharmaceutical Research announced on Feb 17 that it will be presenting at the Wall Street Conference. The event will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach/ Boca Raton, Florida, on Wednesday, March 1, 2017.
Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO) Canopy Growth announced that it has renewed the engagement agreement ("agreement") with XIB Consulting Inc. ("XIB") that the Corporation announced on April 7, 2016 and subsequently renewed October 7, 2016. Under the agreement, XIB will continue to assist Canopy Growth with corporate development initiatives including, but not limited to, acquisitions, strategic networking and market awareness.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Future Farm Technologies Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
-
https://www.newcannabisventures.com/
-
http://www.businessinsider.com/private-equity-companies-focus-on-marijuana-2016-7
-
http://thefreshtoast.com/cannabis/why-this-traditional-brokerage-firm-is-betting-big-on-cannabis/
-
http://www.safeaccessnow.org/major_international_victory_for_medical_cannabis?utm_campaign=ecdd_review&utm_medium=email&utm_source=americansforsafeaccess
-
https://btl.co.za/government-just-approved-medical-marijuana-in-south-africa/
-
http://mjbizdaily.com/an-8-billion-night-7-states-legalize-medical-recreational-cannabis-in-historic-election/
-
http://reason.com/blog/2016/11/08/north-dakota-becomes-the-27th-medical-ma
-
http://mjbizdaily.com/canadian-tribe-could-become-first-of-its-kind-to-grow-medical-cannabis/
-
http://www.politico.com/story/2016/11/marijuana-ballot-measures-activists-watershed-230760
-
https://www.theguardian.com/sustainable-business/2016/oct/22/recreational-marijuana-legalization-big-business
-
http://www.marijuana.com/blog/news/2016/11/obama-federal-prohibition-not-tenable-after-state-marijuana-votes/
-
http://www.pbs.org/newshour/updates/marijuana-legalization-reach-national-tipping-point-election-day/
-
http://thefreethoughtproject.com/war-weed-quicker-realize-all-cannabis-medicinal/
-
http://mjbizdaily.com/marijuana-firms-across-u-s-fund-pro-mmj-bid-in-florida/
-
http://hightimes.com/news/alaskas-first-pot-shop-opens-to-a-long-line-of-customers/
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520cure-1_zpsbn9lurwg.jpg&hash=d762a01d47f957115ea0d588d37e033ba78c3cac) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20cure-1_zpsbn9lurwg.jpg.html)
Great chart
thanks lady D.
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520cure-1_zpsbn9lurwg.jpg&hash=d762a01d47f957115ea0d588d37e033ba78c3cac) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20cure-1_zpsbn9lurwg.jpg.html)
Great chart
-
http://www.thecannabist.co/2016/09/28/israel-cannabis-research/63987/
-
https://cannabis.net/blog/medical/marijuana-doctors-app-aims-to-crush-the-us-government-blocks-on-marijuana-research
-
https://www.rt.com/news/364779-australia-medical-marijuana-cultivation/
-
http://mjbizdaily.com/chart-california-medical-marijuana-sales-skyrocket-132-since-2010/
-
http://www.420magazine.com/forums/international-cannabis-news/294473-what-we-know-about-other-components-cannabis.html?s=6550e251e7e212a3dccd7b51957b9e3b
-
http://www.truth-out.org/news/item/38181-2016-is-biggest-year-ever-for-marijuana-reform-advocates-say
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520cures-1_zpsu28s1fir.jpg&hash=9e155f08e2907494d56fce269d410558e95f2258) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20cures-1_zpsu28s1fir.jpg.html)
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520cure-1_zpsbn9lurwg.jpg&hash=d762a01d47f957115ea0d588d37e033ba78c3cac) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20cure-1_zpsbn9lurwg.jpg.html)
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520ads-410_zpsxowiqsr2.jpg&hash=be5a8115014d4fd976dae1d47b23b603b8cd3c71) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20ads-410_zpsxowiqsr2.jpg.html)
-
(https://www.camelotfantasies.com/proxy.php?request=http%3A%2F%2Fi1322.photobucket.com%2Falbums%2Fu572%2Fspartacus120%2Fcamelot%2520new-2%2Fcannabis%2520ads-903_zpsf0yasr21.png&hash=2a81bc06ae381fff7ae206500119624c8b9da0ed) (http://s1322.photobucket.com/user/spartacus120/media/camelot%20new-2/cannabis%20ads-903_zpsf0yasr21.png.html)
-
http://www.independent.co.uk/news/world/americas/california-cannabis-decriminalisation-vote-nationwide-marijuana-legalisation-a7379436.html
-
https://mjbizdaily.com/canadian-pharmacy-chain-applies-to-dispense-medical-marijuana/
-
http://mjbizdaily.com/israeli-pharmacies-to-start-selling-medical-marijuana/
-
http://www.marijuana.com/blog/news/2016/10/state-marijuana-votes-could-end-federal-prohibition-in-2017/
-
https://blog.mpp.org/research/annual-gallup-poll-shows-record-high-support-making-marijuana-legal/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+blogmpp+%28MPP+Blog%29
-
http://mjbizdaily.com/australian-mmj-company-lists-stock-which-soars/
-
http://www.cnbc.com/2016/10/20/pr-newswire-owc-pharmaceutical-research-corp-completes-development-of-its-medical-cannabis-sublingual-tablet.html
-
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
Oct 20, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
The Proprietary Delivery Mechanism Provides Smoke-Free Alternative For Patients Using Medical Cannabis
PR Newswire
PETACH TIKVA, Israel, October 20, 2016
PETACH TIKVA, Israel, October 20, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
(Photo: http://photos.prnewswire.com/prnh/20161020/430820 )
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
The Company is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country's sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.
Development of the Tablet was overseen by the Company's Director of Research and Regulatory Affairs, Dr. Yehuda Baruch, who established and served as the first Head of the Israeli Ministry of Health's Medical Cannabis (Marijuana) Program from 2003 through 2013. During his tenure, Dr. Baruch treated more than 15,000 patients in Israel with cannabis.
Dr. Baruch commented on the announcement, "Although smoking is the most common way of dosing medical cannabis, while serving as Head of the Israeli Ministry of Health's Medical Cannabis Program, I observed that about fifteen percent of eligible patients do not use medical cannabis because they cannot, or do not want to smoke it. What's more, smoking is not particularly effective for some conditions. We developed the tablet to facilitate the bioavailability and administration of our cannabis formulations to patients. Consistent and accurate dosing is critical to the successful treatment of any condition, and our Tablet is able to deliver that."
Ziv Turner, OWC's CEO, also commented, "We expect that there is a substantial number of eligible patients who are uncomfortable smoking cannabis for medical purposes in the United States as well as other regions, leaving a large segment of the patient population without real access to treatment. We believe our tablet is a preferable administrative method for those, and many other patients, and will make a real difference in the way cannabis is administered."
Mr. Turner went on to say, "We are already in discussion with the Ministry of Health here in Israel, and we have been solicited by a number of licensee candidates looking to bring the technology to the States. Of course we will have to pursue the US market on a state by state basis, as regulations allow."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
-
http://www.otcmarkets.com/stock/OWCP/news/OWC-Pharmaceutical-Research-Corp-Completes-Development-of-Its-Medical-Cannabis-Sublingual-Tablet?id=142876&b=y
-
http://420intel.com/articles/2016/10/19/major-panic-big-pharma-80-now-choose-cannabis-over-prescriptions-pills
-
http://medamerica.co/cannabis-oil-is-gathering-an-unstoppable-momentum-as-a-world-class-healer/
-
http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
-
UK govt admits that medical cannabis works:
http://www.independent.co.uk/news/uk/home-news/cannabis-legality-uk-government-finally-admits-marijuana-has-a-medicinal-effect-a7355941.html
-
medical cannabis finds a market with pets:
http://www.newser.com/story/232326/cannabis-as-catnip-the-new-frontier-in-medical-marijuana.html
-
http://newstarget.com/2016-01-21-u-s-government-finally-admits-that-cannabis-destroys-cancer-cells-and-protects-healthy-cells.html
-
OWCP’s 10 Bagger Potential
October 11, 2016, By OwnTheFloat | Leave a reply
If you want evidence of 10 Bagger potential, simply look at $CBIS. As of October 11th, 2016, $CBIS is trading around $0.02. Considering they have just shy of 2 BILLION in Outstanding Shares, their market cap is $39.5 million.
Do they have substantial revenue and profit? No. $CBIS reported $44,000 in 2015 revenue and lost $18.6 MILLION. Their total assets were $1.8 million, but their Liabilities exceed that as well by about 100%.
$CBIS is also trading on the OTC Pinks, mind you.
Let’s compare these financials, outstanding shares, and market cap to $OWCP now.
First, $OWCP is trading on the OTC QB market – a step up from the Pinks with more requirements on reporting. In other words, usually more “legit”.
$OWCP is currently around $0.05 per share. With their 96.7 million Outstanding Shares, their Market Value is just shy of $4 million.
$OWCP reported a $1.65 million loss last year, but they’ve been in Research & Development mode. Their news today says they expect product launch in Quarter 2 of 2017.
This is huge. There is huge potential for growth far beyond $0.05! Again, it’s unbelievably rare to see an OTC company getting NON-INTEREST BEARING financing. $OWCP isn’t diluting either.
Again, it’s pure speculation and opinion, but tell me why $OWCP can’t see $0.50/share in the coming months when companies like $CBIS (and many others) are seeing those kinds of valuations!
-
http://blog.sfgate.com/smellthetruth/2015/07/08/rheumatoid-arthritis-patients-are-using-medical-marijuana-heres-why/
-
Rheumatoid arthritis patients are using medical marijuana — Here’s why
By David Downs on July 8, 2015 at 8:50 AM
As the greying of America occurs, more and more baby boomers are retiring, and the country is facing a deluge of health-related costs from its aging population.
Chief among those costs is the burden of treating chronic arthritis — a painful, common joint disease for which there is no cure and limited treatment options.
But the greying of America is coinciding with a revolution in the understanding of how medical cannabis works on arthritis pain.
There is a large body of both pre-clinical and patient-reported support for the use of cannabinoid therapy for both rheumatoid arthritis and osteoarthritis. A few clinical trials also exist. The active ingredients in marijuana —“cannabinoids” like THC and CBD — work to suppress immune system over-activity, and this type of over-activity causes the inflammation and pain of rheumatoid arthritis.
-
http://sanfrancisco.cbslocal.com/2016/10/06/nfl-players-push-for-cannabis-alternative-to-opioids-for-chronic-pain/
-
http://reason.com/blog/2016/10/06/where-voters-are-most-likely-to-legalize
-
OWCP an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar").
According to the terms of the agreement:
The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;
Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;
The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.
More details:
Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd.
PR:https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-signs-120000921.html
8k: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11614519 .
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.
Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.
Full Article below Please watch the interview: http://www.baystreet.ca/viewarticle.aspx?id=437873 .
99% of all CANNABIS RESEARCH IS BEING DONE IN ISREAL, OWCP IS AT THE EPICENTER OF THIS WORK
OWCP named one of top 20 Cannabis Stocks by Cannabis Investor Magazine!!!
Cannabis Investor Magazine June Top 20 Cannabis Stocks
-
U.S. pro-marijuana campaigners launch TV ads ahead of November votes
-
Study proves medical marijuana can replace dangerous pharmaceuticals
Tuesday, October 04, 2016 by: Isabelle Z.
Tags: medical marijuana, opioid crisis, harmful medications
Learn more: http://www.naturalnews.com/055525_medical_marijuana_opioid_crisis_harmful_medications.html#ixzz4M9hNj9JC
-
Good
-
folks this is constantly and frequently updated automatically.
just ckick on the link and then click on any heading/title that interests you.
-
http://feeds.denverpost.com/dp-news-marijuana
-
Alaska Becomes Fourth State to Legalize Cannabis:
http://www.cannabisfn.com/alaska-becomes-fourth-state-legalize-cannabis/#.VGLK2Wd0x9A
Alaskans voted to legalize adult-use cannabis earlier this week, becoming the fourth state in the U.S. to do so alongside Colorado, Washington, and Oregon. Measure 2 will legalize the possession, use, and sale of cannabis for recreational use by adults over the age of 21, who will also be permitted to possess up to an ounce and grow up to six plants for their own personal use at home.
The state had been a key battleground for the cannabis legalization movement, with polls prior to the election showing very close support. Alaskan Governor Sean Parnell noted earlier this year that he wasn’t excited about the prospect of legalized marijuana, but would respect the will of the voters and implement the initiative if it were to pass in its third attempt – following similar 2000 and 2004 measures.
Despite the loosening of cannabis laws in 23 U.S. states and the District of Columbia, the federal government continues to consider the drug a Schedule I substance along with heroin and LSD – and more dangerous than ****. The statewide legalizations to date have shown great promise, with an increase in tax revenue, a decrease in violent crimes, and few side effects that many were expecting.
-
Folks please post away and have fun. Here we can post news articles and breaking news about cannabis.